MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-023-01437-1

Медицинская библиотека · Journal of hematology & oncology · 2023

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.

Jin Hua, Zhang Yu, Yu Sijian, Du Xin, Xu Na, Shao Ruoyang, Lin Dongjun, Chen Yanqiu, Xiao Jie, Sun Zhiqiang, Deng Lan, Liang Xinquan, Zhang Hongyu, Guo Ziwen, Dai Min, Shi Pengcheng, Huang Fen, Fan Zhiping, Yin Zhao, Xuan Li, Lin Ren, Jiang Xuejie, Yu Guopan, Liu Qifa

Клиническое исследование II фазыМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R/R AML.

METHODS

This phase 2 trial was done at ten hospitals in China. Eligible patients were R/R AML (aged 18-65 years) with an Eastern Cooperative Oncology Group performance status of 0-2. Patients received venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14) and azacitidine (75 mg/m2 on days 1-7) and homoharringtonine (1 mg/m2 on days 1-7). The primary endpoint was composite complete remission rate [CRc, complete response (CR) plus complete response with incomplete blood count recovery (CRi)] after 2 cycles of treatment. The secondary endpoints include safety and survival.

RESULTS

Between May 27, 2020, and June 16, 2021, we enrolled 96 patients with R/R AML, including 37 primary refractory AML and 59 relapsed AML (16 relapsed after chemotherapy and 43 after allo-HSCT). The CRc rate was 70.8% (95% CI 60.8-79.2). In the patients with CRc, measurable residual disease (MRD)-negative was attained in 58.8% of CRc patients. Accordingly, overall response rate (ORR, CRc plus partial remission (PR)) was 78.1% (95% CI 68.6-85.4). At a median follow-up of 14.7 months (95% CI 6.6-22.8) for all patients, median overall survival (OS) was 22.1 months (95% CI 12.7-Not estimated), and event-free survival (EFS) was 14.3 months (95% CI 7.0-Not estimated). The 1-year OS was 61.5% (95% CI 51.0-70.4), and EFS was 51.0% (95% CI 40.7-60.5). The most common grade 3-4 adverse events were febrile neutropenia (37.4%), sepsis (11.4%), and pneumonia (21.9%).

CONCLUSIONS

VAH is a promising and well-tolerated regimen in R/R AML, with high CRc and encouraging survival. Further randomized studies are needed to be explored. Trial registration clinicaltrials.gov identifier: NCT04424147.

Для цитирования: Jin Hua, Zhang Yu, Yu Sijian, Du Xin, Xu Na, Shao Ruoyang, Lin Dongjun, Chen Yanqiu, Xiao Jie, Sun Zhiqiang, Deng Lan, Liang Xinquan, Zhang Hongyu, Guo Ziwen, Dai Min, Shi Pengcheng, Huang Fen, Fan Zhiping, Yin Zhao, Xuan Li, Lin Ren, Jiang Xuejie, Yu Guopan, Liu Qifa. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.. Journal of hematology & oncology. 2023. DOI: 10.1186/s13045-023-01437-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.